Search

Wenge Shi

from San Marcos, CA
Get Report
Connected to:
Ashley H Shi, 47Chang L Shi, 63Chen S Shi, 43Chong T Shi, 69Cynthia M Shi, 30Danling Shi, 69Danni Shi, 45Di J Shi, 75Frances Shi, 53Ho S Shi, 58

Wenge Shi Phones & Addresses

  • 1537 Crescent Pl, San Marcos, CA 92078 (760) 798-1406
  • 3980 San Leandro Way, San Diego, CA 92130 (760) 798-1406
  • 275 Union Rd, Saint Louis, MO 63108 (314) 361-4098
  • Madison, WI
  • 1537 Crescent Pl, San Marcos, CA 92078

Work

Company: Genoptix medical laboratory, a novartis company Nov 2012 Address: Carlsbad Position: Principal scientist

Education

School / High School: University of Wisconsin-Madison

Skills

Assay Development • Clinical Trials • Clia • Cancer • Biotechnology • Dna Sequencing • Next Gen Sequencing • Flow Cytometry • Clinical Research • Qpcr • Lifesciences • Fish • Immunohistochemistry • Ctc • Luminex • Mentoring • Team Building • Oncology • Molecular Genetics • Next Gen • Molecular Diagnostics • Personalized Medicine • Biomarkers

Languages

English • Mandarin

Ranks

Certificate: Mb(Ascp) (Link)

Interests

Photography

Industries

Pharmaceuticals

Resumes

Resumes

Wenge Shi Photo 1

Associate Scientific Director

View page
Location:
San Diego, CA
Industry:
Pharmaceuticals
Work:
Genoptix Medical Laboratory, A Novartis Company - Carlsbad since Nov 2012
Principal Scientist
Genoptix Medical Laboratory, A Novartis Company - Carlsbad, CA Mar 2011 - Nov 2012
Senior Scientific Investigator
Genoptix - Carlsbad, CA Aug 2007 - Mar 2011
Research Scientist, Scientific Investigator to Scientific Investigator II
Aviva Biosciences Corp. - San Deigo, CA Apr 2006 - Jul 2007
Staff Scientist
Howard Hughes Medical Institute at University of California-San Diego - La Jolla, CA Jul 2001 - Feb 2006
Research Scientist/Postdoc
Education:
University of Wisconsin-Madison
Fudan University
Skills:
Assay Development
Clinical Trials
Clia
Cancer
Biotechnology
Dna Sequencing
Next Gen Sequencing
Flow Cytometry
Clinical Research
Qpcr
Lifesciences
Fish
Immunohistochemistry
Ctc
Luminex
Mentoring
Team Building
Oncology
Molecular Genetics
Next Gen
Molecular Diagnostics
Personalized Medicine
Biomarkers
Interests:
Photography
Languages:
English
Mandarin
Certifications:
Mb(Ascp) (Link)
Mb(Ascp)

Publications

Us Patents

Methods And Compositions For Detecting Rare Cells From A Biological Sample

View page
US Patent:
20080057505, Mar 6, 2008
Filed:
Jul 13, 2007
Appl. No.:
11/777962
Inventors:
Ping Lin - San Diego CA, US
Andrea Ghetti - San Diego CA, US
Wenge Shi - San Marcos CA, US
Mengjia Tang - San Diego CA, US
Gioulnar Harvie - San Diego CA, US
Huimin Tao - San Diego CA, US
Guoliang Tao - San Diego CA, US
Lei Wu - San Diego CA, US
David Cerny - San Diego CA, US
Jia Xu - San Diego CA, US
International Classification:
G01N 33/574
C12Q 1/02
C12Q 1/68
G01N 33/00
US Classification:
435006000, 435029000, 435007230, 435007240, 435007250
Abstract:
The present invention provides methods and compositions for isolating and detecting rare cells from a biological sample containing other types of cells. In particular, the present invention includes a debulking step that uses a microfabricated filters for filtering fluid samples and the enriched rare cells can be used in a downstream process such as identifies, characterizes or even grown in culture or used in other ways. The invention also include a method of determining the aggressiveness of the tumor or of the number or proportion of cancer cells in the enriched sample by detecting the presence or amount of telomerase activity or telomerase nucleic acid or telomerase expression after enrichment of rare cells. This invention further provides an efficient and rapid method to specifically remove red blood cells as well as white blood cells from a biological sample containing at least one of each of red blood cells and white blood cells, resulting in the enrichment of rare target cells including circulating tumor cells (CTC), stromal cells, mesenchymal cells, endothelial cells, fetal cells, stem cells, non-hematopoietic cells etc from a blood sample. The method is based upon combination of immuno-microparticles (antibody coated microparticles) and density-based separation. The final enriched target cells can be subjected to a variety of analysis and manipulations, such as flowcytometry, PCR, immunofluorescence, immunocytochemistry, image analysis, enzymatic assays, gene expression profiling analysis, efficacy tests of therapeutics, culturing of enriched rare cells, and therapeutic use of enriched rare cells. In addition, depleted plasma protein and white blood cells can be optionally recovered, and subjected to other analysis such as inflammation studies, gene expression profiling, etc.

Methods And Compositions For Detecting Rare Cells From A Biological Sample

View page
US Patent:
20080206757, Aug 28, 2008
Filed:
Aug 20, 2007
Appl. No.:
11/841972
Inventors:
Ping LIN - San Diego CA, US
Andrea Ghetti - San Diego CA, US
Wenge Shi - San Marcos CA, US
Mengjia Tang - San Diego CA, US
Gioulnar I. Harvie - San Diego CA, US
Huimin Tao - San Diego CA, US
Guoliang Tao - San Diego CA, US
Lei Wu - San Diego CA, US
David Cerny - San Diego CA, US
Jia Xu - San Diego CA, US
International Classification:
C12Q 1/58
C12N 1/20
G01N 33/53
US Classification:
435 6, 435 30, 435 721
Abstract:
The present invention provides methods and compositions for isolating and detecting rare cells from a biological sample containing other types of cells. In particular, the present invention includes a debulking step that uses a microfabricated filters for filtering fluid samples and the enriched rare cells can be used in a downstream process such as identifies, characterizes or even grown in culture or used in other ways. The invention also include a method of determining the aggressiveness of the tumor or of the number or proportion of cancer cells in the enriched sample by detecting the presence or amount of telomerase activity or telomerase nucleic acid or telomerase expression after enrichment of rare cells. This invention further provides an efficient and rapid method to specifically remove red blood cells as well as white blood cells from a biological sample containing at least one of each of red blood cells and white blood cells, resulting in the enrichment of rare target cells including circulating tumor cells (CTC), stromal cells, mesenchymal cells, endothelial cells, fetal cells, stem cells, non-hematopoietic cells etc from a blood sample. The method is based upon combination of immuno-microparticles (antibody coated microparticles) and density-based separation. The final enriched target cells can be subjected to a variety of analysis and manipulations, such as flowcytometry, PCR, immunofluorescence, immunocytochemistry, image analysis, enzymatic assays, gene expression profiling analysis, efficacy tests of therapeutics, culturing of enriched rare cells, and therapeutic use of enriched rare cells. In addition, depleted plasma protein and white blood cells can be optionally recovered, and subjected to other analysis such as inflammation studies, gene expression profiling, etc.

Methods And Compositions For Detecting Rare Cells From A Biological Sample

View page
US Patent:
20140087358, Mar 27, 2014
Filed:
Sep 17, 2013
Appl. No.:
14/029598
Inventors:
- San Diego CA, US
Andrea GHETTI - San Diego CA, US
Wenge SHI - San Marcos CA, US
Mengjia TANG - San Diego CA, US
Gioulnar I. HARVIE - Santee CA, US
Huimin TAO - San Diego CA, US
Guoliang TAO - San Diego CA, US
Lei WU - San Diego CA, US
David CERNY - Bonita CA, US
Jia XU - Washington DC, US
Assignee:
AVIVA BIOSCIENCES CORPORATION - San Diego CA
International Classification:
C12N 5/09
US Classification:
435 2
Abstract:
The present invention provides methods and compositions for isolating and detecting rare cells from a biological sample containing other types of cells. In particular, the present invention includes a debulking step that uses a microfabricated filters for filtering fluid samples and the enriched rare cells can be used in a downstream process such as identifies, characterizes or even grown in culture or used in other ways. The invention also include a method of determining the aggressiveness of the tumor or of the number or proportion of cancer cells in the enriched sample by detecting the presence or amount of telomerase activity or telomerase nucleic acid or telomerase expression after enrichment of rare cells. This invention further provides an efficient and rapid method to specifically remove red blood cells as well as white blood cells from a biological sample.
Control profile
Wenge Shi from San Marcos, CA Get Report